SUBSCRIBE
SUBSCRIBE
News   Drug Development

Exelixis, Inc. Reports Updated Phase 2 Data for XL184 in Patients With Recurrent Glioblastoma to Be Presented at American Society of Clinical Oncology

March 17, 2010 | 
1 min read
(RTTNews) - Exelixis, Inc. (EXEL: News ) on Thursday reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma, the most common and aggressive form of brain cancer.
Clinical research Phase II
Exelixis, Inc.
MORE ON THIS TOPIC
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac
businessman Climbing mountain. Symbol of success, career, leadership and goal
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac